Abstract
Introduction: Ixekizumab is approved for moderate to severe plaque psoriasis in adults. We report efficacy of ixekizumab for nail, scalp, and palmoplantar psoriasis, and patient-reported psoriasis severity from IXORA-PEDS (NCT03073200), investigating efficacy and safety of ixekizumab in pediatric patients with moderate to severe plaque psoriasis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
